ICA-17043 Pages on BioPortfolio:

BioPortfolio ICA17043
ICA-17043 - BioPortfolio. ... ICA17043 IoGen ISV205 Itax LAF237 LasofoxifeneOporia LEA29Y LibiGel Librel Livial Lucentis Menopausal Levonorgestrel System ...
http://www.bioportfolio.com/search/ICA-17043.html...

BioPortfolio - Johnson and Johnson
... bioportfolio johnson controls in england and wales | hsp27 and patent | The Johnson Johnson Skin Research Center | Johnson and Johnson | ICA-17043 | . ...
http://www.bioportfolio.com/biocorporate/5365-Johnson_and_Jo...

BioPortfolio Biotechnology BioNews : live article
ICA-17043, which is being developed for once-daily oral administration, has received both Orphan Drug Designation and Fast Track Status from the U.S. Food ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=h...

The Impact of the Phase III Pipeline: Future Projections and ...
ICA-17043 IoGen ISV-205 Itax LAF237 Lasofoxifene (Oporia) LEA29Y LibiGel Librel Livial Lucentis Menopausal Levonorgestrel System Mepolizumab ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_415.html...

BioPortfolio Biotechnology BioNews : live article
ICA-17043 for sickle cell disease, for which the Company is conducting a pivotal Phase III clinical trial;. -- a compound for atrial fibrillation, ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=h...

Reticulocyte Count - B0006X1B36 - John B Fuller
including dense red blood cells, reticulocyte count, LDH, and indirect bilirubin, which, taken together, provide significant evidence that ICA-17043 . ...
http://www.bioportfolio.com/bookshop/Operation/ItemSearch/Se...

Sickle Cell Anemia - 0931092221 - Samir K. Ballas
Positive results reported from ICA-17043 phase II trial in sickle cell anemia - Sickle Cell Anemia NewsRxGenomicsGenetics via NewsEdge Corporation : 2005 . ...
http://www.bioportfolio.com/bookshop/SearchIndex/Books/Opera...

Search BioPortfolio: BioPortfolio Web Home Careers Conferences ...
Icagen reports positive results of Phase II clinical trial of ICA-17043 for the treatment of sickle cell anaemia. CHEMICAL BUSINESS NEWSBASE - PRESS RELEASE ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=e...

Biotechnology and Pharmaceutical Industry Search Find Companies ...
Positive results reported from ICA-17043 phase II trial in sickle cell anemia - Sickle Cell Anemia. NewsRxGenomicsGenetics: similar . ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=e...

Results from other life science and pharmaceutical sites:

Dose-escalation study of ICA-17043 in patients wit ...
PubMed is a service of the US National Library of Medicine that includes over 18 million citations from MEDLINE and other life science journals for ...
http://www.ncbi.nlm.nih.gov/pubmed/17064199...

{1} Reports Positive Results Of Phase II Clinical Trial Of ICA ...
Also in this Phase II study, ICA-17043 was well tolerated, ... "We are pleased to report the results of our Phase II study of ICA-17043 for the treatment of ...
http://www.biospace.com/news_story.aspx?NewsEntityId=1835672...

ICA-17043, a novel Gardos channel blocker, prevent...[Blood. 2003 ...
We have developed a chemically novel compound, ICA-17043, ... These data indicate that ICA-17043 is a potent inhibitor of the Gardos channel and ameliorates ...
http://www.ncbi.nlm.nih.gov/pubmed/12433690...

{1} Reports Results Of Phase II Open Label Extension Study Of ICA ...
Icagen, Inc. (ICGN) Reports Results Of Phase II Open Label Extension Study Of ICA-17043 For The Treatment Of Sickle Cell Anemia 10/19/2005 ...
http://www.biospace.com/news_story.aspx?NewsEntityId=2149562...

Efficacy and safety of the Gardos channel blocker,...[Blood. 2008 ...
ICA-17043, a novel Gardos channel blocker, prevents sickled red blood ... 2003]; Dose-escalation study of ICA-17043 in patients with sickle cell disease. ...
http://www.ncbi.nlm.nih.gov/pubmed/18192510...

{1} Receives Milestone Payment From {2} - News, Search Jobs, Events
Icagen has recently completed a Phase II clinical trial of ICA-17043, ... ICA-17043 has received both Orphan Drug Designation and Fast Track Status from the ...
http://www.biospace.com/news_story.aspx?NewsEntityId=1724292...

Sickle cell disease: from membrane pathophysiology...[J Pediatr ...
ICA-17043 is currently in phase 2 human trials. ... 1995]; ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro ...
http://www.ncbi.nlm.nih.gov/pubmed/14663274...

BioSpace offers Pharmaceutical, Biotechnology and Healthcare ...
Icagen, Inc. Reports Positive Results Of Phase II Clinical Trial Of ICA-17043 For The Treatment Of Sickle Cell Anemia 12/7/2004 More. ...
http://www.biospace.com/news_by_disease_results.aspx?TheRxId...

New therapies for sickle cell disease. [Hematol Oncol Clin North ...
[Hematol Oncol Clin North Am. 2004]; ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice ...
http://www.ncbi.nlm.nih.gov/pubmed/16214656...

Icagen Provides Update on Atrial Fibrillation Program
ICA-17043 for sickle cell disease, for which the Company is conducting a pivotal Phase III clinical trial;; a compound for atrial fibrillation, ...
http://www.medscape.com/pages/editorial/pressreleases/pr-crm...

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright 1997-2008 - BioPortfolio Limited.